Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SANUWAVE HealthSNWV -1.75%29 Debt-to-EBITDA is -9.54 as of Mar. 2026. GuruFocus rates SNWV with a GF Score™ of 29/100 and a GF Value™ of $12.19 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 466 Medical Devices & Instruments companies, SANUWAVE Health ranks better than 58.37% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SANUWAVE Health's Debt-to-EBITDA or its related term are showing as below:
SNWV'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.33 Med: -1.4 Max: 8.13
Current: 0.98
During the past 13 years, the highest Debt-to-EBITDA Ratio of SANUWAVE Health was 8.13. The lowest was -3.33. And the median was -1.40.
SNWV's Debt-to-EBITDA is ranked better than 58.37% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs SNWV: 0.98
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SANUWAVE Health Debt-to-EBITDA Related Terms
SANUWAVE Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SANUWAVE Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNWV vs SRTS, COCH, ECOR: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, SANUWAVE Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SANUWAVE Health Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SANUWAVE Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SANUWAVE Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
SANUWAVE Health (SNWV) has a Debt-to-EBITDA of -9.54 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SANUWAVE Health. According to the industry distribution chart, SANUWAVE Health ranks #194 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 41.6%.
Is SANUWAVE Health's Debt-to-EBITDA too high?
SANUWAVE Health's current Debt-to-EBITDA is -9.54. Based on the distribution chart, SANUWAVE Health ranks #194 out of 466 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SANUWAVE Health has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SANUWAVE Health's Debt-to-EBITDA compare to SRTS and COCH?
According to the Medical Devices & Instruments industry distribution chart, SANUWAVE Health ranks #194 out of 466 companies for Debt-to-EBITDA. This puts SANUWAVE Health in the upper half of its industry. The industry median Debt-to-EBITDA is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SANUWAVE Health. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SANUWAVE Health's current Debt-to-EBITDA is -9.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SANUWAVE Health stock overvalued right now?
Based on GuruFocus' analysis, SANUWAVE Health (SNWV) is currently considered Possible Value Trap. The stock's GF Value™ is $12.19, compared to a current price of $6.17 — trading 49.4% below its estimated fair value. The current Debt-to-EBITDA is -9.54. SANUWAVE Health's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SANUWAVE Health (SNWV), the current Debt-to-EBITDA is -9.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SANUWAVE Health (SNWV) Overvalued in 2026?
Based on GuruFocus' analysis, SANUWAVE Health stock appears to be undervalued.
The current stock price of $6.17 is trading 49.4% below its estimated GF Value™ of $12.19.
GuruFocus considers SANUWAVE Health to be Possible Value Trap.
Key valuation signals for SNWV:
Debt-to-EBITDA: -9.54
GF Value™: $12.19 vs. price of $6.17 (49.4% below fair value)
No single metric tells the full story. See the SNWV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
29GF Score
Get the complete analysis for SNWV
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNWV has been successfully added to your 
